Frederico M. Asch, MD presented analysis from his late breaking clinical trial, COAPT. The echocardiography characteristics of the COAPT population, strengthens the need to identify a consistent baseline for enrolling patients in an effort to replicate similar results when used in clinical practice. “…clearly the fact that the results were so different, the outcomes were so different, makes it extremely important that we understand who exactly was enrolled in COAPT,” Asch said. Learn more.
Washington, D.C., (December 4, 2018) —MedStar Heart in partnership with CardioCell has been approved to conduct an investigational new drug clinical trial, called STEMVAD at MedStar Heart & Vascular Institute. The goal of this study is to determine whether stem cell therapy improves myocardial function in patients with severe heart failure. “Innovative therapies to improve heart function and outcomes of patients with advanced heart failure are sorely needed,” said Selma Mohammed, MD, PhD. Read more.
- Walking & Running Forward for Research
Mark your calendars now to connect with other MHRI and MedStar associates by participating in one of...
- Honoring SPIRIT at MHRI: The Ryan White Team
The Ryan White Team was awarded the SPIRIT of Excellence Award for the first quarter of 2019 during ...
- Cardiovascular Research Technologies (CRT) Conference 2020—February 22-25, 2020
Join more than 3,000 interventional and endovascular specialists at Cardiovascular Research Technol...
The researchers from MedStar Heart & Vascular Institute, led by Ron Waksman, MD, found, in their first-of-its-kind trial, that transcatheter aortic valve replacement in patients with low surgical risk showed no deaths or disabling strokes within 30 days of undergoing the procedure. This is a “strong signal” that it is safe for these patients as an alternative to the current standard of care. Read more.